Selected Start-Ups (06/00)
In Vivo summarizes the technologies of several recently founded companies: BioProtocol Inc.'s web site, Bioprotocol.com, will offer life scientists free access to high quality protocols to guide their research. Locus Discovery Inc. has a computational approach for designing small molecule therapeutics that can act as inhibitors or activators of protein activity. Morphotek Inc. is developing an in vivo technology that can alter the genome of microbe, plant, and mammal host cells to produce organisms with commercially viable output traits. NitroOSystems Inc. hopes that its tolerance-free nitrate therapy will become the standard of care for the treatment of angina, congestive heart failure, hypertension, and other cardiovascular disorders. Repair Inc. is developing therapeutics for cardiovascular disease based on its proprietary drug delivery and angiogenesis technologies. Unipharm Technologies Limited claims that its approach to drug delivery will render existing quick dissolve oral dosage forms unnecessary and aid drugs that have negative esophgeal or gastric mucosal effects.
You may also be interested in...
New data seems to indicate an uptick in the percentage of premarket applications that receive a major deficiency letter. See what US FDA spokesperson Alison Hunt said about strategies to avoid them.
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
The Environmental Working Group and US PIRG suggest that beauty and personal-care firms should avoid using talc in loose powders, if not all cosmetic products, and that the US FDA should consider banning the ingredient due to the potential for asbestos contamination, among other concerns.